Mechanism of Musashi2 affecting radiosensitivity of lung cancer by modulating DNA damage repair

Abstract

Identifying new targets for overcoming radioresistance is crucial for improving the efficacy of lung cancer radiotherapy, given that tumor cell resistance is a leading cause of treatment failure. Recent research has spotlighted the significance of Musashi2 (MSI2) in cancer biology. In this study, we first demonstrated that MSI2 plays a key function in regulating the radiosensitivity of lung cancer. The expression of MSI2 is negatively correlated with overall survival in cancer patients, and the knockdown of MSI2 inhibits tumorigenesis and increases radiosensitivity of lung cancer cells. Cellular radiosensitivity, which is closely linked to DNA damage, is influenced by MSI2 interaction with ataxia telangiectasia mutated and Rad3-related kinase (ATR) and checkpoint kinase 1 (CHK1) post-irradiation; moreover, knockdown of MSI2 inhibits the ATR-mediated DNA damage response pathway. RNA-binding motif protein 17 (RBM17), which is implicated in DNA damage repair, exhibits increased interaction with MSI2 post-irradiation. We found that knockdown of RBM17 disrupted the interaction between MSI2 and ATR post-irradiation and increased the radiosensitivity of lung cancer cells. Furthermore, we revealed the potential mechanism of MSI2 recruitment into the nucleus with the assistance of RBM17 to activate ATR to promote radioresistance. This study provides novel insights into the potential application of MSI2 as a new target in lung cancer radiotherapy.

Keywords

ataxia telangiectasia mutated and Rad3-related kinase (ATR) / DNA damage repair / lung cancer / Musashi2 (MSI2) / radioresistance / radiosensitivity / RNA-binding motif protein 17 (RBM17)

References

1	WQ Chen, RS Zheng, PD Baade, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.
2	RL Siegel, KD Miller, HE Fuchs, A Jemal. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.
3	NH Ding, JJ Li, LQ Sun. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr Drug Targets. 2013;14(11):1347-1356.
4	V Mehta. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 2005;63(1):5-24.
5	SL Liauw, PP Connell, RR Weichselbaum. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013;5(173):173sr2.
6	ME Lomax, LK Folkes, P O'Neill. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol. 2013;25(10):578-585.
7	O Mahamud, J So, MLK Chua, RG Bristow. Targeting DNA repair for precision radiotherapy: balancing the therapeutic ratio. Curr Probl Cancer. 2017;41(4):265-272.
8	JA Nickoloff, MK Boss, CP Allen, SM LaRue. Translational research in radiation-induced DNA damage signaling and repair. Transl Cancer Res. 2017;6: S875-S891.
9	DA Proia, RC Bates. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 2014;74(5):1294-1300.
10	YF Wang, H Liu, LX Diao, et al. Hsp90 inhibitor Ganetespib sensitizes non-small cell lung cancer to radiation but has variable effects with chemoradiation. Clin Cancer Res. 2016;22(23):5876-5886.
11	PR de Araujo, A Gorthi, AE da Silva, et al. Musashi1 impacts radio-resistance in glioblastoma by controlling DNA-protein kinase catalytic subunit. Am J Pathol. 2016;186(9):2271-2278.
12	TK Owonikoko, GJ Zhang, XM Deng, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3(6):1579-1594.
13	S Sakakibara, Y Nakamura, H Satoh, H Okano. RNA-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. J Neurosci. 2001;21(20):8091-8107.
14	NA Siddall, EA McLaughlin, NL Marriner, GR Hime. The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. Proc Nat Acad Sci U S A. 2006;103(22):8402-8407.
15	GY Chiou, TW Yang, CC Huang, et al. Musashi-1 promotes a cancer stem cell lineage and chemoresistance in colorectal cancer cells. Sci Rep. 2017;7: 2172.
16	J Sun, WW Sheng, YT Ma, M Dong. Potential role of Musashi-2 RNA-binding protein in cancer EMT. Onco Targets Ther. 2021;14: 1969-1980.
17	CS Potten, C Booth, GL Tudor, et al. Identification of a putative intestinal stem cell and early lineage marker; Musashi-1. Differentiation. 2003;71(1):28-41.
18	S Sakakibara, Y Nakamura, T Yoshida, et al. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Nat Acad Sci U S A. 2002;99(23):15194-15199.
19	XY Wang, LOF Penalva, HY Yuan, et al. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010;9: 221.
20	A Hattori, M Tsunoda, T Konuma, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017;545(7655):500-504.
21	T Ito, HY Kwon, B Zimdahl, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010;466(7307):765-768.
22	SM Park, RP Deering, Y Lu, et al. Musashi-2 controls cell fate, lineage bias, and TGF-β signaling in HSCs. J Exp Med. 2014;211(1):71-87.
23	AE Kudinov, J Karanicolas, EA Golemis, Y Boumber. Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets. Clin Cancer Res. 2017;23(9):2143-2153.
24	AE Kudinov, A Deneka, AS Nikonova, et al. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Nat Acad Sci U S A. 2016;113(25):6955-6960.
25	JC Lin, JT Tsai, TY Chao, HI Ma, CS Chien, WH Liu. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties. Radiother Oncol. 2018;129(2):352-363.
26	AS Chaouki, HK Salz. SPF45: a bifunctional protein with roles in both splicing and DNA repair. PLos Genet. 2006;2(12):1974-1983.
27	N Horikoshi, Y Morozumi, M Takaku, Y Takizawa, H Kurumizaka. Holliday junction-binding activity of human SPF45. Genes Cells. 2010;15(4):373-383.
28	J Sampath, PR Long, RL Shepard, et al. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol. 2003;163(5):1781-1790.
29	O Villamizar, CB Chambers, JM Riberdy, DA Persons, A Wilber. Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis. Oncotarget. 2016;7(12):13810-13826.
30	HJ Qu, L Liu, Z Liu, et al. Blocking TBK1 alleviated radiation-induced pulmonary fibrosis and epithelial?mesenchymal transition through Akt-Erk inactivation. Exp Mol Med. 2019;51: 1-17.
31	L Richards. Radiotherapy: NSCLC treatment-reducing costs and improving outcomes. Nat Rev Clin Oncol. 2010;7(11):610.
32	A Ernst, H Anders, H Kapfhammer, et al. HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Lett. 2015;365(2):211-222.
33	KY Lin, WL Kraus. PARP inhibitors for cancer therapy. Cell. 2017;169(2):183-183.
34	YY Liu, L Conaway, JR Bethard, et al. Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res. 2013;41(9):4949-4962.
35	R Matej, D Housa, P Pouckova, M Zadinova, T Olejar. Radiation-induced production of PAR-1 and TGF-beta 1 mRNA in lung of C57Bl6 and C3H murine strains and influence of pharmacoprophylaxis by ACE inhibitors. Pathol Res Pract. 2007;203(2):107-114.
36	SA Gerber, JYH Lim, KA Connolly, et al. Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer. 2014;134(10):2383-2392.